In the present study, patient-derived xenograft mouse models of esophageal adenocarcinoma (EAC) were used to identify the effects of DC101, a murine VEGFR2 inhibitor, on pharmacokinetics and intratumoral uptake of i.p. administered nab-paclitaxel (NPTX) and aimed to elucidate the mechanisms by which these changes occur. The gene discussed is KDR; the disease is esophageal adenocarcinoma.